|
Middle Cerebral Artery Occlusion
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this work, male rats were treated with JNK-IN-8 after transient middle cerebral artery occlusion, and then the modified improved neurological function score (mNSS), the foot-fault test (FFT), interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) levels were assessed.
|
31541462 |
2020 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of Iba1, tumor necrosis factor-α, interleukin-1β and interleukin-6 was significantly lower in the acacetin group compared with the middle cerebral artery occlusion group.
|
30632500 |
2019 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Results:</b> MCAo resulted in profound attenuation of immune activation, as anticipated. t-PA treatment not only worsened neurological deficit, but further reduced lymphocyte and monocyte counts in blood, enhanced plasma levels of both IL-10 and TNFα and decreased various conventional DC subsets in the spleen and cLN, consistent with enhanced immunosuppression and systemic inflammation after stroke.
|
30972077 |
2019 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, reducing Trim47 apparently decreased the release of pro-inflammatory factors, including interleukin 6 (IL-6), tumor necrosis factor-α (TNF-α) and inducible nitric oxide synthase (iNOS), in brain samples of MCAO rats, which was partly by the blockage of nuclear factor-kappa B (NF-κB) signaling.
|
31178138 |
2019 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
Biomarker
|
disease |
BEFREE |
Following middle cerebral artery occlusion/reperfusion (MCAO/R) surgery, rats were treated orally with 32, 16, and 8 mg/kg AR respectively for 14 days during which cerebral injury was evaluated and proinflammatory factors tumor necrosis factor-α and interleukin-6 as well as neurotrophic factors brain-derived neurotrophic factor and Neurotrophin-3 levels were determined with ELISA kits.
|
31395423 |
2019 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BV2 cells under OGD for 0, 6, 12, or 24 h exhibited decreased USP18 expression and increased expression of the proinflammatory cytokines including interleukin (IL)-1β, IL-6, IL-8, tumor necrosis factor (TNF)-α, and interferon (INF)-γ. Lentiviral overexpression of USP18 in MCAO mice significantly decreased the infarct volume and significantly increased the number of new neurons that coexpressed bromodeoxyuridine (BrdU)/neuronal nuclei (NeuN).
|
31513843 |
2019 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
Biomarker
|
disease |
BEFREE |
The combined administration also regulates the IL-1β and TNF-α in the MCAO rat peripheral blood and ameliorate the brain damage in MCAO rats.
|
29258757 |
2018 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The mRNA expression levels of nod-like receptor protein 3 (NLRP3), tumor necrosis factor alpha (TNF-α), and interleukin-6 (IL-6) and protein expression levels of NLRP3 were assessed. l-Homocarnosine supplementation substantially increased SOD, catalase, Gpx, and GSH levels, whereas it reduced the levels of lipid peroxidation relative to MCAO rats. l-Homocarnosine significantly reduced the infarct area and neurological deficit score, as well as histopathological alteration, apoptosis, and necrosis in brain tissue.
|
29890246 |
2018 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
Biomarker
|
disease |
BEFREE |
The inflammatory cytokines tumor necrosis factor-α (TNFα), interleukin (IL)-1β, and IL-6 of mouse brains after MCAO and BV2 cells treated with oxygen-glucose deprivation were measured using enzyme-linked immunosorbent assay, and apoptotic proteins were examined by Western blotting.
|
30497184 |
2018 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A significant elevation on serum levels of TNF-α and IL-6 was noted with MCAO which was markedly reduced by TFD.
|
30430924 |
2018 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a murine middle cerebral artery occlusion (MCAO) stroke model, HNG ameliorates cerebral infarction and suppresses the production of TNF-α, IL-1β, IL-6 and MCP-1 cytokines.
|
29999240 |
2018 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results of enzyme-linked immunosorbent assay (ELISA) showed that perampanel significantly decreased the expression of pro-inflammatory cytokines IL-1β and TNF-α, whereas it increased the levels of anti-inflammatory cytokines IL-10 and TGF-β1 after MCAO.
|
28401316 |
2018 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also subjected TNF knockout mice to experimental stroke (permanent middle cerebral artery occlusion) and validated the effect of TNF inhibition on EV release.
|
29807527 |
2018 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Endogenous expressions of Gas6 and Axl decreased significantly by 24h after MCAO. rGas6 reduced brain infarction and improved neurologic deficits scores, and increased expression of Axl and decreased the expressions of TRAF3, TRAF6 and inflammatory factors IL-1β, IL-6, and TNF-α.
|
29196212 |
2018 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
Biomarker
|
disease |
BEFREE |
The concentrations of TNF‑α, interleukin (IL)‑1β, IL‑6, and HMGB1 in the group treated with STAT3 inhibitor (MCAO + rapamycin), JAK2 inhibitor (MCAO + AG490), and MCAO + curcumin were significantly lower than in the MCAO group (P<0.01), as well as the relative content of p‑JAK2/JAK2 and p‑STAT3/STAT3 (P<0.05).
|
29393445 |
2018 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Tumor necrosis factor-α and IL-1β mRNA expression markedly increased at 12-hour time point and then returned to the basal level at 24 hours after MCAO; but HSP-70 mRNA expression increased at 24-hour time point.
|
30120034 |
2018 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, vitexin attenuated the secretion of pro-inflammatory cytokine (interleukin (IL)-6 and tumor necrosis factor alpha (TNF-?)) and increased anti-inflammatory cytokine (IL-10) production to ameliorate MCAO-induced inflammation.
|
29710456 |
2018 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
Biomarker
|
disease |
BEFREE |
Western blot analysis shows that vasculotide significantly decreases expression of receptor for advanced glycation end products (RAGE), MCP-1 and TNF-α in the ischemic brain compared with T1DM-MCAo rats.
|
30124060 |
2018 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A significant elevation on serum levels of TNF-α and IL-6 was noted with MCAO which was markedly reduced by TFD.
|
30457456 |
2018 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the IN group had lower expression of interleukin-1β and tumor necrosis factor-α at 6 h after MCAO than the EC group (<i>p</i><0.05).
|
27530114 |
2017 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lig also could effectively decrease the levels of interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in serum and brain tissues of the MCAO rats.
|
28455258 |
2017 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, other important events were observed in MCAO+RIPC group, including substantial decrements in the concentrations of oxidative response indicators [malondialdehyde (MDA), 8-hydroxy-2-deoxyguanosine (8-OHdG), and protein carbonyl], significant reductions in levels of inflammation mediators [myeloperoxidase (MPO), tumor necrosis factor-a (TNF-a), interleukin-1β (IL-1β), and IL-6], and significant decline in neuronal apoptosis revealed by a smaller number of TUNEL-positive cells.
|
27896629 |
2017 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we found that FK866, a potent NAMPT inhibitor, decreased the level of TNF-α, NAMPT and IL-6 in the ischemic brain tissue one day after middle-cerebral-artery occlusion and reperfusion (MCAO/R), improved neurological dysfunction, decreased infarct volume and neuronal loss, and inhibited microgliosis and astrogliosis 14days after MCAO/R.
|
28528966 |
2017 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression levels of interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α) and transforming growth factor-β1 (TGF-β1) were increased, while the level of interleukin-10 (IL-10) was reduced in the infarct cortex 7 days after MCAO, as assessed by immunohistochemistry, western blotting and quantitative real-time PCR (qRT-PCR).
|
27585466 |
2017 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
Biomarker
|
disease |
BEFREE |
In an experimental mouse (C57BL/6NTac) model of middle cerebral artery occlusion (MCAO), we observed that SB mediates neuroprotection by epigenetically regulating the microglial inflammatory response, via downregulating the expression of pro-inflammatory mediators, TNF-α and NOS2, and upregulating the expression of anti-inflammatory mediator IL10, in activated microglia.
|
27722928 |
2017 |